Chr Hansen secures EU approval for 6’-HMO
Image: Chr Hansen
The 6’-SL HMO from Chr Hansen has been approved for highest use levels in infant formula and follow-on formula in the European Union.
As of 4 June 2023, Chr Hansen’s HMO 6’-Sialyllactose sodium salt (6’-SL), marketed under the trademark MyOli 6’-SL HMO, is authorised for the EU market and under proprietary protection for five years. This EU authorisation includes the highest use level for 6’-SL in infant formula and follow-on-formula (0.7g/L) in the EU.
Benefits attributed to 6′-SL HMO are, among others, reducing the risk of adhesion of harmful bacteria and their proteins and support to the brain development in infants, by supplying sialic acid, an essential building block for neurons.
Chr Hansen now has EU authorisation for all five HMOs in its MyOli 5 HMO Mix. The 5 HMO mix contains 2’-FL, 3-FL, LNT, 3’-SL and 6’-SL and is approved for infant formula and follow-on- formula. All these five HMOs are approved at the highest use levels in the industry.
“The fact that Chr Hansen MyOli 5 HMO Mix is now approved for use in the EU at the highest use levels is an important milestone. It means that Chr Hansen can now supply a blend of five HMOs bringing infant nutrition solutions closer to breast milk, to the benefit of infants who cannot be breastfed for various reasons. The European approval is also an important step towards using HMOs at natural concentration levels in infant formula and follow-on formula,” says Jesper Sig Mathiasen, senior vice president, Chr Hansen HMO.
HMOs are the third most abundant solid component of breast milk and are known in many different variations. The benefits stem from the structural diversity of HMOs.
